Product Information
DILTIAZEM 24H ER(LA) 300 MG TB is a generic product labeled by Slate Run Pharmaceuticals LLC, priced at $1.9283 per EA under NDC 70436019804. Its NADAC has been published 179 times since May 3, 2023.
FDA first approved this application on Mar 7, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Slate Run Pharmaceuticals LLCNDC
70436019804
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216439FDA Approved
3/7/2023
TE Code
AB
On Market Since
3/20/2023
Pharmacological Classes
Price Statistics
The NADAC for DILTIAZEM 24H ER(LA) 300 MG TB has been published 179 times since May 3, 2023, and over the history we have for it it has declined 38.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9283 per EA |
|---|---|
| All-time high | $3.1197 (Aug 16, 2023) |
| All-time low | $1.2965 (Jan 21, 2026) |
| 52-week high | $2.7685 |
| 52-week low | $1.2965 |
| Median price | $2.4080 |
| Average price | $2.2952 |
| Largest weekly change | +33.9% (Oct 23, 2024) |
| Weeks tracked | 179 |
| Tracking since | May 3, 2023 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Slate Run Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diltiazem Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DILTIAZEM 24H ER(LA) 300 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for DILTIAZEM 24H ER(LA) 300 MG TB, manufactured by Slate Run Pharmaceuticals LLC, is $1.9283 per EA (NDC 70436019804), effective Sep 30, 2026.
How has the price of DILTIAZEM 24H ER(LA) 300 MG TB changed over time?
Over the history we have for it, the NADAC for DILTIAZEM 24H ER(LA) 300 MG TB has declined 38.2%. It has been tracked across 179 weekly CMS publications since May 3, 2023.
What are the highest and lowest recorded NADAC prices for DILTIAZEM 24H ER(LA) 300 MG TB?
Since May 3, 2023, the NADAC for DILTIAZEM 24H ER(LA) 300 MG TB has ranged from a low of $1.2965 (Jan 21, 2026) to a high of $3.1197 (Aug 16, 2023), with a median of $2.4080 per EA.
Are there cheaper alternatives to DILTIAZEM 24H ER(LA) 300 MG TB?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DILTIAZEM 24H ER(LA) 300 MG TB, is $1.7746 per EA — about 8% below DILTIAZEM 24H ER(LA) 300 MG TB.
Who manufactures DILTIAZEM 24H ER(LA) 300 MG TB?
DILTIAZEM 24H ER(LA) 300 MG TB (NDC 70436019804) is labeled by Slate Run Pharmaceuticals LLC, and CMS classifies it as a generic product.